论文部分内容阅读
超抗原(SAg)是一类能高效地刺激T细胞增殖并且使之释放大量细胞因子的细菌或病毒产物.SAg与抗肿瘤单克隆抗体(McAb)的偶联物或者利用基因工程手段制成的它们的融合蛋白对MHCⅡ类分子阳性或阴性的肿瘤细胞都有强大的杀伤作用.体外细胞毒实验和动物体内实验的研究结果表明,它很有可能成为一种有效的新型肿瘤免疫导向治疗剂.但是目前尚未见临床应用的报道.本文综述了用McAb与SAg结合物介导的T细胞对肿瘤进行免疫导向治疗的实验研究进展.
Super antigen (SAg) is a type of bacteria or virus product that can efficiently stimulate T cell proliferation and release a large number of cytokines. The conjugate of SAg and anti-tumor monoclonal antibody (McAb) or made by genetic engineering Their fusion proteins have a strong killing effect on tumor cells that are positive or negative for MHC class II molecules. In vitro cytotoxicity experiments and animal in vivo experiments have shown that it is likely to become an effective new tumor immuno-guided therapeutic agent. However, no clinical application has been reported yet. This review summarizes the experimental progress of immunoguided therapy of T cells mediated by McAb and SAg conjugates.